Q-omics provides the consensus-scored KIF26B profile across patient tissues and cancer cell-line models. KIF26B expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, KIF26B is differentially expressed in 16, with the highest sampling consensus in HNSC. Additionally, KIF26B RNA expression shows 17,507 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight MESO, HNSC, and TGCT as cancer lineages where KIF26B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KIF26B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KIF26B survival associations across molecular data types. KIF26B RNA expression shows survival associations in the most cancer types (23), followed by mutation status (14) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KIF26B RNA expression–survival associations across cancer types. High KIF26B expression shows unfavorable associations in MESO, OV, ACC, LGG and THCA, but favorable associations in SCLC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for KIF26B RNA expression.
This table summarizes KIF26B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 4. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for KIF26B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KIF26B shows lower tumor expression in KIRC and higher tumor expression in HNSC, BLCA, COAD, LUAD and LUSC. The HNSC box plot shows higher KIF26B RNA expression in tumor versus normal tissue (log2 FC = +2.661, t-test p < 0.001).
This table shows molecular features associated with KIF26B in patient tissues and cancer cell lines. In patient samples, KIF26B shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, KIF26B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in CNS and LARGE_INTESTINE.
